Literature DB >> 7768507

Interaction of human gallbladder mucin with calcium hydroxyapatite: binding studies and the effect on hydroxyapatite formation.

S M Qiu1, G Wen, J Wen, R D Soloway, R S Crowther.   

Abstract

Calcium hydroxyapatite (HAP) crystals formed in vitro in the presence of polymeric human gallbladder mucin (1.0 mg/mL) were smaller (0.75 +/- 0.39 microns) than control crystals (7.86 +/- 2.76 microns), but the mucin did not affect the kinetics of crystal formation or alter the amount of mineral phase present at equilibrium. In contrast, glycopeptide subunits produced by proteolysis of the native mucin had no effect on HAP crystal size. Both native mucin and glycopeptides bound to mature HAP crystals, but the glycopeptides were much more readily displaced by phosphate ions. Therefore, in experiments where HAP was being formed, the phosphate ions inhibited the interaction of glycopeptides with the nascent HAP. These results indicate that gallbladder mucin may modulate HAP formation in vivo, and that this ability may be altered during pathological states, such as neutrophil infiltration or bacterial colonization, that may cause the release of proteinases capable of digesting mucin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768507

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  3 in total

1.  Activation of human neutrophils by calcium carbonate polymorphs.

Authors:  H M Burt; J K Jackson; D R Taylor; R S Crowther
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

Review 2.  Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2013-02-28

Review 3.  Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer.

Authors:  Bo Lin; Qiujiao Wang; Kun Liu; Xu Dong; Mingyue Zhu; Mengsen Li
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.